111 related articles for article (PubMed ID: 25939514)
1. Replication of a genetic variant for prostate cancer-specific mortality.
Penney KL; Shui IM; Feng Z; Sesso HD; Stampfer MJ; Stanford JL
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):260-3. PubMed ID: 25939514
[TBL] [Abstract][Full Text] [Related]
2. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.
FitzGerald LM; Zhao S; Leonardson A; Geybels MS; Kolb S; Lin DW; Wright JL; Eeles R; Kote-Jarai Z; Govindasami K; Giles GG; Southey MC; Schleutker J; Tammela TL; Sipeky C; Penney KL; Stampfer MJ; Gronberg H; Wiklund F; Stattin P; Hugosson J; Karyadi DM; Ostrander EA; Feng Z; Stanford JL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):228-237. PubMed ID: 29298992
[TBL] [Abstract][Full Text] [Related]
3. Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.
Sanchez A; Schoenfeld JD; Nguyen PL; Fiorentino M; Chowdhury D; Stampfer MJ; Sesso HD; Giovannucci E; Mucci LA; Shui IM
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):197-201. PubMed ID: 26926928
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Shui IM; Lindström S; Kibel AS; Berndt SI; Campa D; Gerke T; Penney KL; Albanes D; Berg C; Bueno-de-Mesquita HB; Chanock S; Crawford ED; Diver WR; Gapstur SM; Gaziano JM; Giles GG; Henderson B; Hoover R; Johansson M; Le Marchand L; Ma J; Navarro C; Overvad K; Schumacher FR; Severi G; Siddiq A; Stampfer M; Stevens VL; Travis RC; Trichopoulos D; Vineis P; Mucci LA; Yeager M; Giovannucci E; Kraft P
Eur Urol; 2014 Jun; 65(6):1069-75. PubMed ID: 24411283
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
[TBL] [Abstract][Full Text] [Related]
6. Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families.
Karyadi DM; Zhao S; He Q; McIntosh L; Wright JL; Ostrander EA; Feng Z; Stanford JL
Int J Cancer; 2015 May; 136(9):2166-71. PubMed ID: 25273821
[TBL] [Abstract][Full Text] [Related]
7. Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality.
Zelic R; Fiano V; Ebot EM; Coseo Markt S; Grasso C; Trevisan M; De Marco L; Delsedime L; Zugna D; Mucci LA; Richiardi L
Prostate Cancer Prostatic Dis; 2019 May; 22(2):284-291. PubMed ID: 30341411
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.
Lin DW; FitzGerald LM; Fu R; Kwon EM; Zheng SL; Kolb S; Wiklund F; Stattin P; Isaacs WB; Xu J; Ostrander EA; Feng Z; Grönberg H; Stanford JL
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1928-36. PubMed ID: 21846818
[TBL] [Abstract][Full Text] [Related]
9. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Wang V; Geybels MS; Jordahl KM; Gerke T; Hamid A; Penney KL; Markt SC; Freedman M; Pomerantz M; Lee GM; Rana H; Börnigen D; Rebbeck TR; Huttenhower C; Eeles RA; Stanford JL; Consortium P; Berndt SI; Claessens F; Sørensen KD; Park JY; Vega A; Usmani N; Mucci L; Sweeney CJ
Prostate; 2021 Jul; 81(10):683-693. PubMed ID: 33956343
[TBL] [Abstract][Full Text] [Related]
11. CYP17 polymorphisms and prostate cancer outcomes.
Wright JL; Kwon EM; Lin DW; Kolb S; Koopmeiners JS; Feng Z; Ostrander EA; Stanford JL
Prostate; 2010 Jul; 70(10):1094-101. PubMed ID: 20503394
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
Gu C; Li Q; Zhu Y; Qu Y; Zhang G; Wang M; Yang Y; Wang J; Jin L; Wei Q; Ye D
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):310-6. PubMed ID: 26238235
[TBL] [Abstract][Full Text] [Related]
14. Variation in selenoenzyme genes and prostate cancer risk and survival.
Geybels MS; Hutter CM; Kwon EM; Ostrander EA; Fu R; Feng Z; Stanford JL; Peters U
Prostate; 2013 May; 73(7):734-42. PubMed ID: 23143801
[TBL] [Abstract][Full Text] [Related]
15. Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
Wang Y; Jacobs EJ; Gapstur SM; Maliniak ML; Gansler T; McCullough ML; Stevens VL; Patel AV
Eur Urol; 2017 Dec; 72(6):931-939. PubMed ID: 28711382
[TBL] [Abstract][Full Text] [Related]
16. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer.
Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Lu TL; Chiang HC; Bao BY
Sci Rep; 2015 Sep; 5():14045. PubMed ID: 26365175
[TBL] [Abstract][Full Text] [Related]
18. Established prostate cancer susceptibility variants are not associated with disease outcome.
Wiklund FE; Adami HO; Zheng SL; Stattin P; Isaacs WB; Grönberg H; Xu J
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1659-62. PubMed ID: 19423541
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility loci associated with prostate cancer progression and mortality.
Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K
Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480
[TBL] [Abstract][Full Text] [Related]
20. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
